

Serotyping results in 56 non OT patients in Germany							
	ID	6 I/III	6 d-I/III	6 II	6 d-II	7 II	SAG1
NR	1	1.2	1.0	1.0	1.0	1.1	4.2
	2	1.0	0.9	0.9	0.9	0.9	5.6
	3	1.3	1.1	1.1	0.9	0.9	5.1
	4	1.4	1.3	1.3	1.3	1.1	11.2
	5	1.4	1.4	1.9	2.4	2.3	12.0
	6	1.2	1.2	4.1	4.3	1.2	15.2
	7	1.4	1.0	2.2	2.7	3.8	13.3
	8	1.0	0.9	1.5	1.2	1.3	9.5
	9	1.2	1.0	1.6	1.2	2.1	9.6
	10	1.1	0.9	1.0	1.3	2.0	3.5
	11	1.3	1.1	1.7	1.5	1.2	9.8
	12	1.4	0.9	2.5	1.7	2.2	6.2
	13	1.0	1.0	1.8	1.6	1.5	3.2
	14	0.0	1.3	3.3	3.5	14.3	6.8
	15	1.1	1.1	1.6	1.6	2.3	4.5
	16	1.2	1.1	2.2	2.4	1.5	13.2
	17	0.7	1.2	1.0	1.3	1.6	8.6
	18	1.0	1.4	1.6	2.4	2.3	12.0
	19	1.3	0.9	1.3	1.8	1.5	12.7
	20	1.1	1.3	2.5	1.4	1.5	14.2
Type II	21	1.4	1.0	2.3	2.0	1.8	14.5
	22	1.0	1.1	1.1	1.3	1.6	6.3
	23	1.4	1.1	1.9	2.2	1.4	2.5
	24	1.2	0.9	1.7	1.7	1.5	9.7
	25	1.1	1.2	1.4	1.4	2.5	7.5
	26	1.1	1.0	1.1	1.1	2.0	21.6
	27	1.4	1.0	1.9	1.3	1.6	1.5
	28	1.2	1.0	1.0	1.0	2.2	9.1
	29	1.1	0.9	1.0	1.1	1.9	12.6
	30	1.4	1.4	1.6	1.4	1.6	12.6
	31	1.2	1.2	1.2	1.2	7.9	13.0
	32	0.8	0.8	1.6	1.6	6.5	3.7
	33	1.0	0.9	1.3	1.3	2.2	15.7
	34	0.8	0.8	1.5	2.4	1.3	20.3
	35	1.0	0.9	1.0	2.0	4.0	10.4
	36	0.9	0.8	0.8	1.6	3.0	1.5
	37	0.9	0.9	1.1	1.2	1.5	3.3
	38	1.0	0.9	1.8	2.6	15.7	6.3
	39	1.4	1.3	2.3	1.3	3.0	17.5
	40	1.2	1.1	1.7	1.7	1.3	6.0
	41	1.1	1.0	1.1	2.5	1.5	1.1
	42	0.9	1.0	1.1	1.1	2.0	13.5
	43	1.1	1.1	1.2	1.2	1.7	2.5
I or III	44	3.1	1.1	1.0	1.0	1.3	22.9
	45	2.1	1.2	1.1	1.2	0.8	6.0
	46	2.0	1.0	1.1	1.4	0.9	5.9
	47	1.7	1.2	1.1	1.1	1.0	13.4
	48	1.6	0.9	1.0	1.3	1.1	5.5
	49	1.7	1.6	1.2	1.3	1.4	8.0
Atypical	50	1.9	1.1	1.5	1.2	1.0	5.3
	51	2.2	1.1	1.9	0.9	1.0	7.8
	52	2.1	1.5	4.2	1.3	6.5	3.1
	53	1.8	3.4	5.7	3.5	13.9	13.5
	54	3.1	4.3	3.7	4.3	3.1	2.5
	55	1.8	1.4	2.4	2.2	1.2	13.6
	56	3.7	1.1	1.2	1.2	2.1	25.1

Supplemental Table 2\_Shobab et. al.

7%

70%

11%

12%